 |
|
UM School of Medicine researchers find extreme genetic variability in malaria parasite
October 15, 2009Study in Mali, West Africa indicates possibility of vaccine-resistant malaria
Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world. While there is no approved vaccine for malaria, various experimental vaccines are in development. The CVD study suggests that developing a broadly protective vaccine for malaria may be challenging because the parasite's genetic makeup is so variable, constantly changing. If a vaccine targets only a single protein in the parasite, and there are many different versions of that protein, the parasite becomes a moving target for vaccine development. Drug-resistant malaria has been a major barrier to treating the disease, and this CVD study suggests that "vaccine-resistant" malaria may also become a problem. The study is being published in the Oct. 14 issue of the journal Science Translational Medicine.
Scientists and health officials worldwide have made eradication of the disease a priority, with an effective and broadly protective vaccine a critical step toward that goal. Malaria - a parasite spread to humans through mosquito bites - is prevented by avoiding mosquito bites using bed nets or by killing mosquitoes with insecticides. The parasite is treatable using medications, although drug resistance is a relatively common problem. According to the World Health Organization, a child dies of malaria every 30 seconds. There are approximately 300 million malaria cases annually worldwide, resulting in more than one million deaths, most of them African children.
Certain regions within a key parasite protein - a protein targeted by some experimental malaria vaccines - seem to affect the human immune response more than others, and targeting those areas could help develop a better vaccine, according to the study led by Shannon Takala, Ph.D., assistant professor of medicine at the University of Maryland School of Medicine and a research scientist in the CVD. The study was conducted in collaboration with researchers at the University of Bamako in Mali, West Africa, and at the Center for Bioinformatics and Computational Biology and Department of Biology at the University of Maryland, College Park.
"This brings us one step closer to being able to design a broadly protective malaria vaccine," says Dr. Takala. "Though there are medications that are used to treat malaria, drug resistance is a recurring problem. An effective vaccine could help us eliminate malaria altogether, a public health goal that is attracting more global support than ever before."
"In addition to its home campus in Baltimore, the University of Maryland School of Medicine employs hundreds of researchers in 23 countries around the globe," says E. Albert Reece, M.D., Ph.D., M.B.A., dean of the School of Medicine, vice president for medical affairs of the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor. "This study is an example of how our global footprint allows School of Medicine researchers to study diseases such as malaria in the very regions of the world in which they are devastating to the population."
A research team of Malian and American scientists at the CVD's outpost in Mali, West Africa tested malaria parasites from 100 children in Mali over a three-year period. The children, who had not been vaccinated against the disease, all experienced repeated malaria infections during the three years. The CVD researchers, including Christopher Plowe, M.D., M.P.H., Howard Hughes Medical Institute investigator, professor of medicine and chief of the Malaria Section at the University of Maryland School of Medicine, looked at the genetic diversity in a surface protein of the Plasmodium falciparum - the AMA-1 protein - that is the target of some candidate malaria vaccines.
By tracking the changes in the AMA-1 protein each time a child became infected with malaria, researchers found a surprising amount of genetic diversity. Among more than 500 separate malaria infections the children experienced throughout the study, researchers found 214 distinct types of the AMA-1 protein. The scientists also found that the genetic differences in certain parts of the protein but not others corresponded to whether or not a child got sick the next time they were infected with malaria. It was easier for a child's immune system to defend itself against illness in a subsequent infection if the protein in the second parasite was genetically similar to the parasite that caused their first illness.
Working with Michael P. Cummings, Ph.D., associate professor of biology at the University of Maryland, the researchers were able to track which variants of the AMA-1 protein were present in each infection and compare that data to the symptoms each child experienced during the infections.
"Applying a molecular evolutionary perspective to the study of the malaria parasite gave us new information about why it has been so challenging to develop an effective malaria vaccine," says Dr. Cummings, who is affiliated with the University of Maryland's Center for Bioinformatics and Computational Biology. "The genetic diversity we found in the AMA-1 protein was so high that it could potentially thwart the usefulness of any vaccine based on this protein."
By narrowing their focus to those specific regions of the protein that are recognized as distinct by the immune response, the researchers were able to reduce the number of immunologically important AMA-1 types from 214 to just 25. By targeting those specific regions of the protein, scientists could possibly develop a more broadly protective malaria vaccine.
"The emergence of drug-resistant malaria was one of the main reasons eradication of the disease didn't work when it was tried 50 years ago," says senior author Dr. Plowe. "We want people to begin thinking now about the possibility that 'vaccine-resistant malaria' could be just as much of a problem for the new global eradication effort. We need to come up with ways to beat vaccine-resistant malaria before we start losing vaccines to resistance the way we have lost so many good drugs."
University of Maryland Medical Center
Certain regions within a key parasite protein - a protein targeted by some experimental malaria vaccines - seem to affect the human immune response more than others, and targeting those areas could help develop a better vaccine, according to the study led by Shannon Takala, Ph.D., assistant professor of medicine at the University of Maryland School of Medicine and a research scientist in the CVD. The study was conducted in collaboration with researchers at the University of Bamako in Mali, West Africa, and at the Center for Bioinformatics and Computational Biology and Department of Biology at the University of Maryland, College Park.
"This brings us one step closer to being able to design a broadly protective malaria vaccine," says Dr. Takala. "Though there are medications that are used to treat malaria, drug resistance is a recurring problem. An effective vaccine could help us eliminate malaria altogether, a public health goal that is attracting more global support than ever before."
"In addition to its home campus in Baltimore, the University of Maryland School of Medicine employs hundreds of researchers in 23 countries around the globe," says E. Albert Reece, M.D., Ph.D., M.B.A., dean of the School of Medicine, vice president for medical affairs of the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor. "This study is an example of how our global footprint allows School of Medicine researchers to study diseases such as malaria in the very regions of the world in which they are devastating to the population."
A research team of Malian and American scientists at the CVD's outpost in Mali, West Africa tested malaria parasites from 100 children in Mali over a three-year period. The children, who had not been vaccinated against the disease, all experienced repeated malaria infections during the three years. The CVD researchers, including Christopher Plowe, M.D., M.P.H., Howard Hughes Medical Institute investigator, professor of medicine and chief of the Malaria Section at the University of Maryland School of Medicine, looked at the genetic diversity in a surface protein of the Plasmodium falciparum - the AMA-1 protein - that is the target of some candidate malaria vaccines.
By tracking the changes in the AMA-1 protein each time a child became infected with malaria, researchers found a surprising amount of genetic diversity. Among more than 500 separate malaria infections the children experienced throughout the study, researchers found 214 distinct types of the AMA-1 protein. The scientists also found that the genetic differences in certain parts of the protein but not others corresponded to whether or not a child got sick the next time they were infected with malaria. It was easier for a child's immune system to defend itself against illness in a subsequent infection if the protein in the second parasite was genetically similar to the parasite that caused their first illness.
Working with Michael P. Cummings, Ph.D., associate professor of biology at the University of Maryland, the researchers were able to track which variants of the AMA-1 protein were present in each infection and compare that data to the symptoms each child experienced during the infections.
"Applying a molecular evolutionary perspective to the study of the malaria parasite gave us new information about why it has been so challenging to develop an effective malaria vaccine," says Dr. Cummings, who is affiliated with the University of Maryland's Center for Bioinformatics and Computational Biology. "The genetic diversity we found in the AMA-1 protein was so high that it could potentially thwart the usefulness of any vaccine based on this protein."
By narrowing their focus to those specific regions of the protein that are recognized as distinct by the immune response, the researchers were able to reduce the number of immunologically important AMA-1 types from 214 to just 25. By targeting those specific regions of the protein, scientists could possibly develop a more broadly protective malaria vaccine.
"The emergence of drug-resistant malaria was one of the main reasons eradication of the disease didn't work when it was tried 50 years ago," says senior author Dr. Plowe. "We want people to begin thinking now about the possibility that 'vaccine-resistant malaria' could be just as much of a problem for the new global eradication effort. We need to come up with ways to beat vaccine-resistant malaria before we start losing vaccines to resistance the way we have lost so many good drugs."
University of Maryland Medical Center
Malaria Current Events and Malaria News RSSOn the Trail of a Vaccine for Lyme Disease: Yale Researchers Target Tick Saliva
A protein found in the saliva of ticks helps protect mice from developing Lyme disease, Yale researchers have discovered. The findings, published in the November 19 issue of Cell Host & Microbe, may spur development of a new vaccine against infection from Lyme disease, which is spread through tick bites.
Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria
A rapid and accurate diagnosis is the first step towards treatment in the fight against infectious disease.
Small nanoparticles bring big improvement to medical imaging
If you're watching the complex processes in a living cell, it is easy to miss something important-especially if you are watching changes that take a long time to unfold and require high-spatial-resolution imaging.
Prioritizing low-cost, simple health measures would save 2.5 million child lives a year
Almost a third of the children under age five who die each year could be saved if governments rebalance health spending to ensure low-cost, simple interventions such as safe water and hygiene, bed nets and basic maternal and newborn care, leading aid agency World Vision said today. Currently, 8.8 million children a year die before age five, most of preventable causes.
Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year.
U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
DNA barcodes: Creative new uses span health, fraud, smuggling, history, more
The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others.
PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.
Global challenges and opportunities in fighting HIV/AIDS and neglected diseases
Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs.
More Malaria Current Events and Malaria News Articles
 |
The Making of a Tropical Disease: A Short History of Malaria (Johns Hopkins Biographies of Disease) by Randall M. Packard (Author) Malaria sickens hundreds of millions of people -- and kills one to three million -- each year. Despite massive efforts to eradicate the disease, it remains a major public health problem in poorer tropical regions. But malaria has not always been concentrated in tropical areas. How did other regions control malaria and why does the disease still flourish in some parts of the globe? From Russia to Bengal to Palm Beach, Randall Packard's far-ranging narrative traces the natural and social forces that help malaria spread and make it deadly. He finds that war, land development, crumbling health systems, and globalization -- coupled with climate change and changes in the distribution and flow of water -- create conditions in which malaria's carrier mosquitoes thrive. The combination of... |
 |
The Malaria Capers : More Tales of Parasites and People, Research and Reality by Robert S. Desowitz (Author) "Reads like a murder mystery. . . . [Desowitz] writes with uncommon lucidity and verse, leaving the reader with a vivid understanding of malaria and other tropical diseases, and the ways in which culture, climate and politics have affected their spread and containment."—New York Times Why, Robert S. Desowitz asks, has biotechnical research on malaria produced so little when it had promised so much? An expert in tropical diseases, Desowtiz searches for answers in this provocative book. . |
 |
Humanity's Burden: A Global History of Malaria (Studies in Environment and History) by James L.A. Webb Jr. (Author) Humanity's Burden provides a panoramic overview of the history of malaria. It traces the long arc of malaria out of tropical Africa into Eurasia, its transfer to the Americas during the early years of the Columbian exchange, and its retraction from the middle latitudes into the tropics since the late nineteenth century. Adopting a broadly comparative approach to historical patterns and processes, it synthesizes research findings from the natural and social sciences and weaves these understandings into a narrative that reaches from the earliest evidence of malaria infections in tropical Africa up to the present. Written in a style that is easily accessible to non-specialists, it considers the significance of genetic mutations, diet, lifestyle, migration, warfare, palliative and curative... |
 |
Compiled 1981-1984 by Malaria! |
 |
First Comes Love, Then Comes Malaria: How a Peace Corps Poster Boy Won My Heart and a Third World Adventure Changed My Life by Eve Brown-Waite (Author) In this laugh-out-loud funny memoir, a pampered city girl falls head over little black heels in love with a Peace Corps poster boy and follows him —literally–to the ends of the earth. Eve Brown always thought she would join the Peace Corps someday, although she secretly worried about life without sushi, frothy coffee drinks and air conditioning. But with college diploma in hand, it was time to put up or shut up. So with some ambivalence she arrives at the Peace Corps office–sporting her best safari chic attire –to casually look into the steps one might take if one were to become a global humanitarian, a la Angelina Jolie. But when Eve meets John, her dashing young Peace Corps recruiter, all her ambivalence flies out the window. She absolutely must join the Peace Corps -... |
 |
Parasites! - The Malaria Parasite by Sheila Wyborny (Author) Malaria is a serious disease caused by a tiny mosquito-borne parasite called Plasmodium. It once affected entire empires, but thanks to the work of health organizations, malaria is now mostly confined to warm, moist climates. Scientists are still at work today, however, developing methods of curing the disease and destroying its carriers. |
 |
Molecular Approaches to Malaria by Irwin W. Sherman (Editor) "Molecular Approaches to Malaria" provides an overview of the rapid and significant developments that have occurred in malaria research, including the 2002 genome sequencing of Plasmodium falciparum and its mosquito vector, Anopheles gambiae. This work: provides a concise source of up-to-date research findings; appeals to a diverse audience, including malaria researchers, teachers, investigators, and public health professionals; offers contributions by recognized malaria researchers with practical experience; and, presents comprehensive coverage of topics including a clearly written introduction to Plasmodium molecular biology. |
![GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy]](http://ecx.images-amazon.com/images/I/21%2BeHMzjARL._SL160_.jpg) |
GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy] by Giant Microbes GIANTmicrobes are fun and educationala great way to learn about various health topics and the microscopic critters that are found in and around us. Each microbe character is 5-7 in size--over a million times their actual size! Perfect for teachers, parents and budding scientiststhey also make humorous gifts. Each microbe comes with an information tag including scientific name, an image of the actual microbe, and a mini history and science lesson. Not suitable for children under 3 years. Our products are made by top manufacturers who care about toy safety, quality and value. Your order will ship factory fresh directly from our warehouse to your door. We carefully inspect and beautifully package every order before shipment to ensure that you receive high quality products that are... |
 |
Malaria: Fever Wars Starring: Artist Not Provided |
 |
Malaria: Poverty, Race, and Public Health in the United States by Margaret Humphreys (Author) In Malaria: Poverty, Race, and Public Health in the United States, Margaret Humphreys presents the first book-length account of the parasitic, insect-borne disease that has infected millions and influenced settlement patterns, economic development, and the quality of life at every level of American society, especially in the south. Humphreys approaches malaria from three perspectives: the parasite's biological history, the medical response to it, and the patient's experience of the disease. It addresses numerous questions including how the parasite thrives and eventually becomes vulnerable, how professionals came to know about the parasite and learned how to fight them, and how people view the disease and came to the point where they could understand and support the struggle... |
| © 2009 BrightSurf.com |